0.00Open0.00Pre Close0 Volume0 Open Interest80.00Strike Price0.00Turnover185.49%IV-68.55%PremiumDec 20, 2024Expiry Date174.40Intrinsic Value100Multiplier25DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9957Delta0.0001Gamma1.46Leverage Ratio-0.0389Theta0.0540Rho1.45Eff Leverage0.0084Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet